menù
Phase: Phase II-III clinical trials
Principal Investigator: Associate Professor Licitra Lisa Francesca Linda
Main Facility: Medical Oncology 3 – Head and Neck Cancers
Drug: INBRX-106 Pembrolizumab
Phase: Phase II clinical trials
Principal Investigator: Dr. Brambilla Marta
Main Facility: Medical Oncology 1
Drug: V940
Phase: Phase I-II clinical trials
Principal Investigator: Dott. Del Vecchio Michele
Main Facility: Medical Oncology 1 – Medical Oncology Unit: Melanoma
Drug: Pembrolizumab, V940
Principal Investigator: Dr. Lo Russo Giuseppe
Main Facility: Thoracic Oncology Unit
Drug: Visugromab (CTL-002)
Principal Investigator: Dr. Damian Silvia
Main Facility: Phase 1 Clinical Trials Unit (Early Clinical Drug Development Team – ECDD)
Drug: MK-1084, Cetuximab
Principal Investigator: Dott. Duca Matteo
Drug: HER3-DXd
Drug: Adagrasib Pembrolizumab
Drug: BMS-986504
Principal Investigator: Dr. Procopio Giuseppe
Main Facility: Genitourinary Medical Oncology
Drug: V940 e BCG
Principal Investigator: Dr. Pietrantonio Filippo
Main Facility: Gastrointestinal Oncology
Drug: Amivantamab sottocute (farmaco sperimentale)
Drug: GSK5764227 (experimental drug)
Drug: Precemtabart Tocentecan (M9140)
Drug: ifinatamab deruxtecan (I-DXd)
Principal Investigator: Dott. Occhipinti Mario
Drug: MK-6070 e Ifinatamab Derux-tecan (MK-2400)
Principal Investigator: Dott.ssa Verzoni Elena
Drug: Ifinatamab Deruxtecan
Drug: S241656 (BDTX-4933)
Drug: HER3-DXd=patritumab deruxtecan
Drug: MK-2870 (SKB264; sacituzumab tirumotecan; sac-TMT)
Principal Investigator: Dr. Di Nicola Massimo
Drug: BMS-986482, Nivolumab, Relatlimab, Bevacizumab
Drug: MK-2870 + ENFORTUMAB VEDOTIN (EV) IN COMBINATION WITH PEMBROLIZUMAB
Sign up for our newsletter to stay informed about news, events, and updates from the Institute
Subscribe